Omigapil treatment decreases fibrosis and improves respiratory rate in dy2J mouse model of congenital muscular dystrophy

Authors

Qing Yu, Children's National Medical Center, Washington, DC
Arpana Sali, Children’s National Medical Center, Washington, DC
Jack Van der Meulen, Children's National Medical Center, Washington, DC
Brittany K. Creeden, Children's National Medical Center, Washington, DC
Heather Gordish-Dressman, George Washington UniversityFollow
Anne Rutkowski, Kaiser SCPMG, Olathe, KS
Sree Rayavarapu, George Washington University
Kitipong Uaesoontrachoon, Children's National Medical Center, Washington, DC
Tony Huynh, Children's National Medical Center, Washington, DC
Kanneboyina Nagaraju, George Washington UniversityFollow
Christopher F. Spurney, George Washington UniversityFollow

Document Type

Journal Article

Publication Date

6-6-2013

Journal

PLoS ONE

Volume

Volume 8, Issue 6

Inclusive Pages

Article number e65468

Keywords

Forelimb--drug effects; Hindlimb--drug effects; Muscle, Skeletal--drug effects; Muscular Dystrophy, Animal--drug therapy; Oxepins--pharmacology; Respiratory Rate--drug effects

Comments

Reproduced with permission ofPLoS ONE

Creative Commons License

This work is licensed under a Creative Commons Attribution 3.0 License.

APA Citation

Yu, Q., Sali, A., Van der Meulen, J., Creeden, B.K., Gordish-Dressman, H., et al. (2013) Omigapil Treatment Decreases Fibrosis and Improves Respiratory Rate in dy2J Mouse Model of Congenital Muscular Dystrophy. PLoS ONE 8(6): e65468.

Peer Reviewed

1

Open Access

1